CA
INSY

Continental Advisors’s Insys Therapeutics, Inc. INSY Stock Holding History

Continental Advisors’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-10,000
Closed -$285K – 177
2015
Q3 		$285K Sell
10,000
-22,000
-69% -$810K 0.08% 148
2015
Q2 		$1.15M Buy
+32,000
New +$997K 0.31% 94

Other funds holding INSY

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FHAM
Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return
GAM
Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return

Continental Advisors's INSY Position: Q4 2015 in Review

Continental Advisors sold out of Insys Therapeutics, Inc. (INSY) in Q4 2015, closing a stake of 8,400 shares — an estimated $239K sold.

Continental Advisors first reported a position in INSY in Q3 2015 and held it in 1 quarter. The position peaked at $239K in Q3 2015. 154 funds tracked by Wall St. Rank hold INSY as of Q4 2015.

  • Continental Advisors reported no remaining Insys Therapeutics, Inc. position as of Q4 2015 after selling out during the quarter.
  • Continental Advisors sold 8,400 Insys Therapeutics, Inc. shares in Q4 2015, an estimated $239K.
  • Continental Advisors first reported a position in Insys Therapeutics, Inc. in Q3 2015 and held it in 1 quarter.
  • Continental Advisors's Insys Therapeutics, Inc. position peaked at $239K in Q3 2015.
  • 154 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q4 2015.

Based on Continental Advisors's 13F filing for Q4 2015, filed 12 Feb 2016.